Biological E. Limited - Revision history

UpdateBot: robot: Update article (please report if you notice any mistake or error in this edit)

2022-04-03T19:05:00Z

robot: Update article (please report if you notice any mistake or error in this edit)

← Older revision		Revision as of 00:35, 4 April 2022
Line 9:		Line 9:
	\| image_size =		\| image_size =
	\| image_caption =		\| image_caption =
	\| type = [[Private ~~Limited Company~~]]		\| type = [[Private company\|Private]]
	\| founder = Datla Venkata Krishnam Raju		\| founder = Datla Venkata Krishnam Raju
	\| key_people = Mahima Datla (Managing Director)<ref>{{cite news \|title=Hyderabad's Biological E: The Dark Horse In India's Vaccine Race \|url=https://www.forbesindia.com/article/innovation/hyderabads-biological-e-the-dark-horse-in-indias-vaccine-race/64733/1 \|access-date=24 May 2021 \|work=Forbes India \|language=en}}</ref>		\| key_people = Mahima Datla (Managing Director)<ref>{{cite news \|title=Hyderabad's Biological E: The Dark Horse In India's Vaccine Race \|url=https://www.forbesindia.com/article/innovation/hyderabads-biological-e-the-dark-horse-in-indias-vaccine-race/64733/1 \|access-date=24 May 2021 \|work=Forbes India \|language=en}}</ref>
Line 37:		Line 37:
	{{main article\|Corbevax}}		{{main article\|Corbevax}}

	During the [[COVID-19 pandemic]], the company signed a pact with [[Baylor College of Medicine]] and Dynavax Technologies to ~~manufacture~~ a [[COVID-19 vaccine]].<ref>{{Cite web\|url=https://www.livemint.com/news/india/biological-e-starts-human-trials-of-baylor-college-s-covid-19-vaccine-11605525030199.html\|title=Biological E initiates human trials of vaccine\|first=Leroy\|last=Leo\|date=16 November 2020\|website=mint}}</ref><ref>{{cite news \|title=Coronavirus {{!}} Biological E. inks pacts with Johnson & Johnson, Baylor College of Medicine on vaccine \|url=https://www.thehindu.com/business/Industry/coronavirus-biological-e-inks-pacts-with-johnson-johnson-baylor-college-of-medicine-on-vaccine/article32345582.ece \|access-date=21 March 2021 \|work=The Hindu \|date=13 August 2020 \|language=en-IN}}</ref> The vaccine Corbevax<ref>{{Cite web\|last=Bharadwaj\|first=Swati\|date=3 June 2021\|title=Bio E to get Rs 1,500 crore advance from government to reserve 30 crore doses of Corbevax\|url=https://timesofindia.indiatimes.com/business/india-business/bio-e-to-get-rs-1500-crore-advance-from-government-to-reserve-30-crore-doses-of-corbevax/articleshow/83197897.cms\|url-status=live\|access-date=2021-06-03\|website=The Times of India\|language=en}}</ref>/[[Bio E COVID-19]] is expected to rollout in ~~August~~ 2021 with 75 to 80 million doses manufactured per month; the production expected to reach 1 billion by the end of 2022 under the [[Quadrilateral Security Dialogue\|Quad initiative]].<ref>{{cite news \|title=Meet Bio E: India’s Oldest Private Vaccine Maker Making 1 Billion Covid Doses \|url=https://www.indiatimes.com/technology/news/bio-e-india-vaccine-maker-making-1-billion-covid-doses-539279.html \|access-date=24 May 2021 \|work=IndiaTimes \|date=2021-05-02 \|language=en-IN}}</ref><ref>{{cite news \|title=Biological E covid vaccine: Biological E set for Covid vaccine rollout by August\|url=https://timesofindia.indiatimes.com/business/india-business/biological-e-set-for-covid-vaccine-rollout-by-august/articleshow/82445644.cms \|access-date=24 May 2021 \|work=The Times of India \|language=en}}</ref>		During the [[COVID-19 pandemic]], the company signed a pact with [[Baylor College of Medicine]], [[Texas Children's Hospital]] and Dynavax Technologies to develop a [[COVID-19 vaccine]].<ref>{{Cite web\|url=https://www.livemint.com/news/india/biological-e-starts-human-trials-of-baylor-college-s-covid-19-vaccine-11605525030199.html\|title=Biological E initiates human trials of vaccine\|first=Leroy\|last=Leo\|date=16 November 2020\|website=mint}}</ref><ref>{{cite news \|title=Coronavirus {{!}} Biological E. inks pacts with Johnson & Johnson, Baylor College of Medicine on vaccine \|url=https://www.thehindu.com/business/Industry/coronavirus-biological-e-inks-pacts-with-johnson-johnson-baylor-college-of-medicine-on-vaccine/article32345582.ece \|access-date=21 March 2021 \|work=The Hindu \|date=13 August 2020 \|language=en-IN}}</ref> The vaccine Corbevax<ref>{{Cite web\|last=Bharadwaj\|first=Swati\|date=3 June 2021\|title=Bio E to get Rs 1,500 crore advance from government to reserve 30 crore doses of Corbevax\|url=https://timesofindia.indiatimes.com/business/india-business/bio-e-to-get-rs-1500-crore-advance-from-government-to-reserve-30-crore-doses-of-corbevax/articleshow/83197897.cms\|url-status=live\|access-date=2021-06-03\|website=The Times of India\|language=en\|archive-url=https://web.archive.org/web/20210603065628/http://timesofindia.indiatimes.com/business/india-business/bio-e-to-get-rs-1500-crore-advance-from-government-to-reserve-30-crore-doses-of-corbevax/articleshow/83197897.cms \|archive-date=3 June 2021 }}</ref>/[[Bio E COVID-19]] is expected to rollout in 2021 with 75 to 80 million doses manufactured per month; the production is expected to reach 1 billion doses by the end of 2022 under the [[Quadrilateral Security Dialogue\|Quad initiative]].<ref>{{cite news \|title=Meet Bio E: India’s Oldest Private Vaccine Maker Making 1 Billion Covid Doses \|url=https://www.indiatimes.com/technology/news/bio-e-india-vaccine-maker-making-1-billion-covid-doses-539279.html \|access-date=24 May 2021 \|work=IndiaTimes \|date=2021-05-02 \|language=en-IN}}</ref><ref>{{cite news \|title=Biological E covid vaccine: Biological E set for Covid vaccine rollout by August\|url=https://timesofindia.indiatimes.com/business/india-business/biological-e-set-for-covid-vaccine-rollout-by-august/articleshow/82445644.cms \|access-date=24 May 2021 \|work=The Times of India \|language=en}}</ref>

	In August 2020, the company signed a deal with [[Johnson & Johnson]] to manufacture the latter's vaccine candidate at its Hyderabad facility.<ref>{{cite news \|title=Biological E to manufacture Janssen's Covid-19 vaccine \|url=https://www.pharmaceutical-technology.com/news/biological-e-covid-vaccine-deals/ \|access-date=24 May 2021 \|work=www.pharmaceutical-technology.com}}</ref> In February 2021, it announced that it will produce over 600 million doses of the single-dose [[Janssen COVID-19 vaccine\|Janssen vaccine]] annually.<ref>{{cite news \|title=Biological E looking to make 600 million Johnson and Johnson vaccine shots a year \|url=https://timesofindia.indiatimes.com/india/biological-e-looking-to-make-600-million-johnson-and-johnson-vaccine-shots-a-year/articleshow/80783227.cms \|access-date=21 March 2021 \|work=The Times of India \|language=en}}</ref><ref>{{cite news \|last1=Leo \|first1=Leroy \|title=Biological E: The mass producer of Johnson & Johnson vaccine \|url=https://www.livemint.com/companies/news/biological-e-the-mass-producer-of-johnson-johnson-vaccine-11616235431098.html \|access-date=21 March 2021 \|work=mint \|date=20 March 2021 \|language=en}}</ref>		In August 2020, the company signed a deal with [[Johnson & Johnson]] to manufacture the latter's vaccine candidate at its Hyderabad facility.<ref>{{cite news \|title=Biological E to manufacture Janssen's Covid-19 vaccine \|url=https://www.pharmaceutical-technology.com/news/biological-e-covid-vaccine-deals/ \|access-date=24 May 2021 \|work=www.pharmaceutical-technology.com}}</ref> In February 2021, it announced that it will produce over 600 million doses of the single-dose [[Janssen COVID-19 vaccine\|Janssen vaccine]] annually.<ref>{{cite news \|title=Biological E looking to make 600 million Johnson and Johnson vaccine shots a year \|url=https://timesofindia.indiatimes.com/india/biological-e-looking-to-make-600-million-johnson-and-johnson-vaccine-shots-a-year/articleshow/80783227.cms \|access-date=21 March 2021 \|work=The Times of India \|language=en}}</ref><ref>{{cite news \|last1=Leo \|first1=Leroy \|title=Biological E: The mass producer of Johnson & Johnson vaccine \|url=https://www.livemint.com/companies/news/biological-e-the-mass-producer-of-johnson-johnson-vaccine-11616235431098.html \|access-date=21 March 2021 \|work=mint \|date=20 March 2021 \|language=en}}</ref>
Line 46:		Line 46:
	{{Authority control}}		{{Authority control}}

	~~{{COVID19-vaccine-stub}}~~

	[[Category:Biotechnology companies of India]]		[[Category:Biotechnology companies of India]]
Line 53:		Line 52:
	[[Category:Indian companies established in 1953]]		[[Category:Indian companies established in 1953]]
	[[Category:Biopharmaceutical companies]]		[[Category:Biopharmaceutical companies]]
			[[Category:COVID-19 vaccine producers]]

imported>Rexh17: Added covid19 vaccine stub template

2021-08-17T00:58:59Z

Added covid19 vaccine stub template

← Older revision		Revision as of 06:28, 17 August 2021
Line 39:		Line 39:
	During the [[COVID-19 pandemic]], the company signed a pact with [[Baylor College of Medicine]] and Dynavax Technologies to manufacture a [[COVID-19 vaccine]].<ref>{{Cite web\|url=https://www.livemint.com/news/india/biological-e-starts-human-trials-of-baylor-college-s-covid-19-vaccine-11605525030199.html\|title=Biological E initiates human trials of vaccine\|first=Leroy\|last=Leo\|date=16 November 2020\|website=mint}}</ref><ref>{{cite news \|title=Coronavirus {{!}} Biological E. inks pacts with Johnson & Johnson, Baylor College of Medicine on vaccine \|url=https://www.thehindu.com/business/Industry/coronavirus-biological-e-inks-pacts-with-johnson-johnson-baylor-college-of-medicine-on-vaccine/article32345582.ece \|access-date=21 March 2021 \|work=The Hindu \|date=13 August 2020 \|language=en-IN}}</ref> The vaccine Corbevax<ref>{{Cite web\|last=Bharadwaj\|first=Swati\|date=3 June 2021\|title=Bio E to get Rs 1,500 crore advance from government to reserve 30 crore doses of Corbevax\|url=https://timesofindia.indiatimes.com/business/india-business/bio-e-to-get-rs-1500-crore-advance-from-government-to-reserve-30-crore-doses-of-corbevax/articleshow/83197897.cms\|url-status=live\|access-date=2021-06-03\|website=The Times of India\|language=en}}</ref>/[[Bio E COVID-19]] is expected to rollout in August 2021 with 75 to 80 million doses manufactured per month; the production expected to reach 1 billion by the end of 2022 under the [[Quadrilateral Security Dialogue\|Quad initiative]].<ref>{{cite news \|title=Meet Bio E: India’s Oldest Private Vaccine Maker Making 1 Billion Covid Doses \|url=https://www.indiatimes.com/technology/news/bio-e-india-vaccine-maker-making-1-billion-covid-doses-539279.html \|access-date=24 May 2021 \|work=IndiaTimes \|date=2021-05-02 \|language=en-IN}}</ref><ref>{{cite news \|title=Biological E covid vaccine: Biological E set for Covid vaccine rollout by August\|url=https://timesofindia.indiatimes.com/business/india-business/biological-e-set-for-covid-vaccine-rollout-by-august/articleshow/82445644.cms \|access-date=24 May 2021 \|work=The Times of India \|language=en}}</ref>		During the [[COVID-19 pandemic]], the company signed a pact with [[Baylor College of Medicine]] and Dynavax Technologies to manufacture a [[COVID-19 vaccine]].<ref>{{Cite web\|url=https://www.livemint.com/news/india/biological-e-starts-human-trials-of-baylor-college-s-covid-19-vaccine-11605525030199.html\|title=Biological E initiates human trials of vaccine\|first=Leroy\|last=Leo\|date=16 November 2020\|website=mint}}</ref><ref>{{cite news \|title=Coronavirus {{!}} Biological E. inks pacts with Johnson & Johnson, Baylor College of Medicine on vaccine \|url=https://www.thehindu.com/business/Industry/coronavirus-biological-e-inks-pacts-with-johnson-johnson-baylor-college-of-medicine-on-vaccine/article32345582.ece \|access-date=21 March 2021 \|work=The Hindu \|date=13 August 2020 \|language=en-IN}}</ref> The vaccine Corbevax<ref>{{Cite web\|last=Bharadwaj\|first=Swati\|date=3 June 2021\|title=Bio E to get Rs 1,500 crore advance from government to reserve 30 crore doses of Corbevax\|url=https://timesofindia.indiatimes.com/business/india-business/bio-e-to-get-rs-1500-crore-advance-from-government-to-reserve-30-crore-doses-of-corbevax/articleshow/83197897.cms\|url-status=live\|access-date=2021-06-03\|website=The Times of India\|language=en}}</ref>/[[Bio E COVID-19]] is expected to rollout in August 2021 with 75 to 80 million doses manufactured per month; the production expected to reach 1 billion by the end of 2022 under the [[Quadrilateral Security Dialogue\|Quad initiative]].<ref>{{cite news \|title=Meet Bio E: India’s Oldest Private Vaccine Maker Making 1 Billion Covid Doses \|url=https://www.indiatimes.com/technology/news/bio-e-india-vaccine-maker-making-1-billion-covid-doses-539279.html \|access-date=24 May 2021 \|work=IndiaTimes \|date=2021-05-02 \|language=en-IN}}</ref><ref>{{cite news \|title=Biological E covid vaccine: Biological E set for Covid vaccine rollout by August\|url=https://timesofindia.indiatimes.com/business/india-business/biological-e-set-for-covid-vaccine-rollout-by-august/articleshow/82445644.cms \|access-date=24 May 2021 \|work=The Times of India \|language=en}}</ref>

	In August 2020, the company signed a deal with [[Johnson & Johnson]] to manufacture the latter's vaccine candidate at its Hyderabad facility.<ref>{{cite news \|title=Biological E to manufacture Janssen's Covid-19 vaccine \|url=https://www.pharmaceutical-technology.com/news/biological-e-covid-vaccine-deals/ \|access-date=24 May 2021 \|work=www.pharmaceutical-technology.com}}</ref> In February 2021, it announced that it will produce over 600 million doses of the single-dose [[~~Johnson & Johnson~~ COVID-19 vaccine\|~~Johnson & Johnson~~ vaccine]] annually.<ref>{{cite news \|title=Biological E looking to make 600 million Johnson and Johnson vaccine shots a year \|url=https://timesofindia.indiatimes.com/india/biological-e-looking-to-make-600-million-johnson-and-johnson-vaccine-shots-a-year/articleshow/80783227.cms \|access-date=21 March 2021 \|work=The Times of India \|language=en}}</ref><ref>{{cite news \|last1=Leo \|first1=Leroy \|title=Biological E: The mass producer of Johnson & Johnson vaccine \|url=https://www.livemint.com/companies/news/biological-e-the-mass-producer-of-johnson-johnson-vaccine-11616235431098.html \|access-date=21 March 2021 \|work=mint \|date=20 March 2021 \|language=en}}</ref>		In August 2020, the company signed a deal with [[Johnson & Johnson]] to manufacture the latter's vaccine candidate at its Hyderabad facility.<ref>{{cite news \|title=Biological E to manufacture Janssen's Covid-19 vaccine \|url=https://www.pharmaceutical-technology.com/news/biological-e-covid-vaccine-deals/ \|access-date=24 May 2021 \|work=www.pharmaceutical-technology.com}}</ref> In February 2021, it announced that it will produce over 600 million doses of the single-dose [[Janssen COVID-19 vaccine\|Janssen vaccine]] annually.<ref>{{cite news \|title=Biological E looking to make 600 million Johnson and Johnson vaccine shots a year \|url=https://timesofindia.indiatimes.com/india/biological-e-looking-to-make-600-million-johnson-and-johnson-vaccine-shots-a-year/articleshow/80783227.cms \|access-date=21 March 2021 \|work=The Times of India \|language=en}}</ref><ref>{{cite news \|last1=Leo \|first1=Leroy \|title=Biological E: The mass producer of Johnson & Johnson vaccine \|url=https://www.livemint.com/companies/news/biological-e-the-mass-producer-of-johnson-johnson-vaccine-11616235431098.html \|access-date=21 March 2021 \|work=mint \|date=20 March 2021 \|language=en}}</ref>

	==References==		==References==
Line 45:		Line 45:

	{{Authority control}}		{{Authority control}}

			{{COVID19-vaccine-stub}}

	[[Category:Biotechnology companies of India]]		[[Category:Biotechnology companies of India]]

>ChandlerMinh at 06:56, 10 June 2021

2021-06-10T06:56:30Z

New page

{{Short description|Indian biopharmaceutical company}}
{{EngvarB|date=April 2014}}
{{Use dmy dates|date=April 2014}}
{{Infobox company
| name = Biological E Limited
| logo = Biological E logo.jpg
| logo_caption =
| image =
| image_size =
| image_caption =
| type = [[Private Limited Company]]
| founder = Datla Venkata Krishnam Raju
| key_people = Mahima Datla (Managing Director)<ref>{{cite news |title=Hyderabad's Biological E: The Dark Horse In India's Vaccine Race |url=https://www.forbesindia.com/article/innovation/hyderabads-biological-e-the-dark-horse-in-indias-vaccine-race/64733/1 |access-date=24 May 2021 |work=Forbes India |language=en}}</ref>
| foundation = {{start date and age|1953}}
| location = [[Jubilee Hills, Hyderabad, Telangana]], India
| num_employees = 2500
| industry = [[Biotechnology]], [[Biopharmaceutical]]s
| products =
| revenue =
| Value =
| net_income =
| homepage = {{url|www.biologicale.com}}
}}

'''Biological E Limited''' (also known as '''BioE''') is an Indian [[biotechnology]] and [[biopharmaceutical]] company based in [[Hyderabad, Telangana]]. It specialises in the areas of low-cost vaccine production.<ref>{{cite web|url=http://www.thehindubusinessline.com/companies/biological-e-cuts-childrens-vaccine-price-by-30/article4634028.ece |title=Biological E cuts children's vaccine price by 30% |publisher=thehindubusinessline.com/ |date= |access-date=19 April 2013}}</ref>

==History==
The company was founded by Dr. D.V.K. Raju and Mr. G.A.N. Raju in 1953 as Biological Products Private Limited. It was among the first private sector companies in India to manufacture biological products.<ref>{{cite web|url=http://www.icra.in/Files/Reports/Rationale/Biological_E_%20-R-11262010.pdf |title=Biological E Limited |publisher=icra.in |date= |access-date=13 March 2012}}</ref> It pioneered Heparin production in India.<ref name="about">{{cite web |title=Setting up manufacturing facilities for Pneumococcal Conjugate Vaccine. |url=http://tdb.gov.in/wp-content/uploads/2017/01/Write-up_BiologicalE.pdf |website=www.tdb.gov.in |publisher=[[Technology Development Board]] |access-date=25 April 2021}} {{PD-notice}}</ref>

In 1964, Evans Medicals, a U.K. based Pharma Company, which later got merged with Glaxo SmithKline acquired 40% stake in the company, which was subsequently bought back by the promoters in 1995.{{Citation needed|date=April 2021}}

During the 1960s and 70s, Biological E developed formulations in cough and digestive enzymes, started manufacturing anti-tetanus serum, and launched anti-TB drugs, TT and DTP vaccines.<ref name="about"/>

Biological E embarked specialise in low-cost vaccines manufacturing. The company started manufacturing its flagship vaccine product, Pentavalent (DTP Hib HepB) in 2008.<ref name="about"/> Biological E is a major supplier of vaccines to international development and aid organisations such as [[WHO]], [[UNICEF]], [[BMGF]].<ref name="about"/>

==COVID-19 vaccine development==
{{main article|Corbevax}}

During the [[COVID-19 pandemic]], the company signed a pact with [[Baylor College of Medicine]] and Dynavax Technologies to manufacture a [[COVID-19 vaccine]].<ref>{{Cite web|url=https://www.livemint.com/news/india/biological-e-starts-human-trials-of-baylor-college-s-covid-19-vaccine-11605525030199.html|title=Biological E initiates human trials of vaccine|first=Leroy|last=Leo|date=16 November 2020|website=mint}}</ref><ref>{{cite news |title=Coronavirus {{!}} Biological E. inks pacts with Johnson & Johnson, Baylor College of Medicine on vaccine |url=https://www.thehindu.com/business/Industry/coronavirus-biological-e-inks-pacts-with-johnson-johnson-baylor-college-of-medicine-on-vaccine/article32345582.ece |access-date=21 March 2021 |work=The Hindu |date=13 August 2020 |language=en-IN}}</ref> The vaccine Corbevax<ref>{{Cite web|last=Bharadwaj|first=Swati|date=3 June 2021|title=Bio E to get Rs 1,500 crore advance from government to reserve 30 crore doses of Corbevax|url=https://timesofindia.indiatimes.com/business/india-business/bio-e-to-get-rs-1500-crore-advance-from-government-to-reserve-30-crore-doses-of-corbevax/articleshow/83197897.cms|url-status=live|access-date=2021-06-03|website=The Times of India|language=en}}</ref>/[[Bio E COVID-19]] is expected to rollout in August 2021 with 75 to 80 million doses manufactured per month; the production expected to reach 1 billion by the end of 2022 under the [[Quadrilateral Security Dialogue|Quad initiative]].<ref>{{cite news |title=Meet Bio E: India’s Oldest Private Vaccine Maker Making 1 Billion Covid Doses |url=https://www.indiatimes.com/technology/news/bio-e-india-vaccine-maker-making-1-billion-covid-doses-539279.html |access-date=24 May 2021 |work=IndiaTimes |date=2021-05-02 |language=en-IN}}</ref><ref>{{cite news |title=Biological E covid vaccine: Biological E set for Covid vaccine rollout by August|url=https://timesofindia.indiatimes.com/business/india-business/biological-e-set-for-covid-vaccine-rollout-by-august/articleshow/82445644.cms |access-date=24 May 2021 |work=The Times of India |language=en}}</ref>

In August 2020, the company signed a deal with [[Johnson & Johnson]] to manufacture the latter's vaccine candidate at its Hyderabad facility.<ref>{{cite news |title=Biological E to manufacture Janssen's Covid-19 vaccine |url=https://www.pharmaceutical-technology.com/news/biological-e-covid-vaccine-deals/ |access-date=24 May 2021 |work=www.pharmaceutical-technology.com}}</ref> In February 2021, it announced that it will produce over 600 million doses of the single-dose [[Johnson & Johnson COVID-19 vaccine|Johnson & Johnson vaccine]] annually.<ref>{{cite news |title=Biological E looking to make 600 million Johnson and Johnson vaccine shots a year |url=https://timesofindia.indiatimes.com/india/biological-e-looking-to-make-600-million-johnson-and-johnson-vaccine-shots-a-year/articleshow/80783227.cms |access-date=21 March 2021 |work=The Times of India |language=en}}</ref><ref>{{cite news |last1=Leo |first1=Leroy |title=Biological E: The mass producer of Johnson & Johnson vaccine |url=https://www.livemint.com/companies/news/biological-e-the-mass-producer-of-johnson-johnson-vaccine-11616235431098.html |access-date=21 March 2021 |work=mint |date=20 March 2021 |language=en}}</ref>

==References==
{{Reflist}}

{{Authority control}}

[[Category:Biotechnology companies of India]]
[[Category:Manufacturing companies based in Hyderabad, India]]
[[Category:Pharmaceutical companies established in 1953]]
[[Category:Indian companies established in 1953]]
[[Category:Biopharmaceutical companies]]